Digest Network Come funziona
Network
/
Società
Al
Non verificato

Almirall, S.A.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

11 comunicati stampa

Guarda tutti i comunicati
10/11/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato azionario
Pubblico Esercizio/Vendita al dettaglio
Almirall’s 2025 9M Results
Fonte
Almirall, S.A.
Emittente
Business Wire
1.00
0
18/09/2025
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 2025
Fonte
Almirall, S.A.
Emittente
Business Wire
1.00
0
17/09/2025
Scienza
Sanità
Farmaceutica
Vetrine/Shopping
Giovani
Medicina - Varie
Biotecnologia
Terza età
Salute
Eventi
Industria
EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology
Fonte
Almirall, S.A.
Emittente
Business Wire
1.00
0
25/07/2025
Scienza
Finanza
Associazioni/Professionisti
Biotecnologia
Salute
Farmaceutica
Sanità
Pubblico Esercizio/Vendita al dettaglio
Eventi
Mercato azionario
Almirall H1 2025 Results
Fonte
Almirall, S.A.
Emittente
Business Wire
1.00
0
12/05/2025
Almirall Q1 2025 Results
Fonte
Almirall, S.A.
Emittente
Business Wire
1.00
0
07/03/2025
Multimedialità
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
AAD 2025: Almirall presents early-stage pipeline progress and real-world evidence on demonstrating AK treatment success and patient satisfaction with Tirbanibulin
Fonte
Almirall, S.A.
Emittente
Business Wire
1.00
0
06/03/2025
Almirall Announces CFO Transition Plan and Appoints Jon U. Garay Alonso as CFO to Succeed Mike McClellan in August 2025
Fonte
Almirall, S.A.
Emittente
Business Wire
1.00
0
24/02/2025
Multimedialità
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato azionario
Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline
Fonte
Almirall, S.A.
Emittente
Business Wire
1.00
0
11/11/2024
Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth
Fonte
Almirall, S.A.
Emittente
Business Wire
1.00
0
15/10/2024
Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
Fonte
Almirall, S.A.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0